Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
EX-32.1 - EX-32.1 - Q Therapeutics, Inc.d900336dex321.htm
EX-31.2 - EX-31.2 - Q Therapeutics, Inc.d900336dex312.htm
EX-31.1 - EX-31.1 - Q Therapeutics, Inc.d900336dex311.htm
EX-23.1 - EX-23.1 - Q Therapeutics, Inc.d900336dex231.htm
EX-10.4.1 - EX-10.4.1 - Q Therapeutics, Inc.d900336dex1041.htm
10-K - 10-K - Q Therapeutics, Inc.d900336d10k.htm
EX-21.1 - EX-21.1 - Q Therapeutics, Inc.d900336dex211.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Q Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven J. Borst, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 31, 2015 By:

/s/ STEVEN J. BORST

Steven J. Borst, M.B.A.

Chief Financial Officer and Vice President of

Corporate Development (Principal Financial

Officer, Principal Accounting Officer)